TW202408534A - 用於治療癌症的別位及正位ｅｇｆｒ抑制劑之組合 - Google Patents

用於治療癌症的別位及正位ｅｇｆｒ抑制劑之組合 Download PDF

Info

Publication number
TW202408534A
TW202408534A TW112117726A TW112117726A TW202408534A TW 202408534 A TW202408534 A TW 202408534A TW 112117726 A TW112117726 A TW 112117726A TW 112117726 A TW112117726 A TW 112117726A TW 202408534 A TW202408534 A TW 202408534A
Authority
TW
Taiwan
Prior art keywords
combination
methyl
indazol
mmol
egfr inhibitor
Prior art date
Application number
TW112117726A
Other languages
English (en)
Chinese (zh)
Inventor
喬治 雅克
布魯諾 摩托葛里歐
依凡 艾莉絲 內格爾
山德 克麗希塔 奧瑞克 歐斯特
安東尼歐 瑞奇
Original Assignee
瑞士商赫孚孟拉羅股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商赫孚孟拉羅股份公司 filed Critical 瑞士商赫孚孟拉羅股份公司
Publication of TW202408534A publication Critical patent/TW202408534A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW112117726A 2022-05-13 2023-05-12 用於治療癌症的別位及正位ｅｇｆｒ抑制劑之組合 TW202408534A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP22173211.8 2022-05-13
EP22173211 2022-05-13
EP22175302 2022-05-25
EP22175302.3 2022-05-25

Publications (1)

Publication Number Publication Date
TW202408534A true TW202408534A (zh) 2024-03-01

Family

ID=86558741

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112117726A TW202408534A (zh) 2022-05-13 2023-05-12 用於治療癌症的別位及正位ｅｇｆｒ抑制劑之組合

Country Status (9)

Country Link
US (1) US20260007678A1 (enExample)
EP (1) EP4522113A1 (enExample)
JP (1) JP2025516543A (enExample)
KR (1) KR20250009977A (enExample)
CN (1) CN119173253A (enExample)
AU (1) AU2023268579A1 (enExample)
CA (1) CA3255503A1 (enExample)
TW (1) TW202408534A (enExample)
WO (1) WO2023217924A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020254565A1 (en) 2019-06-21 2020-12-24 F. Hoffmann-La Roche Ag Egfr inhibitors for the treatment of cancer
WO2022117475A1 (en) 2020-12-01 2022-06-09 F. Hoffmann-La Roche Ag New indazole derivatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020254565A1 (en) * 2019-06-21 2020-12-24 F. Hoffmann-La Roche Ag Egfr inhibitors for the treatment of cancer
WO2022117487A1 (en) * 2020-12-01 2022-06-09 F. Hoffmann-La Roche Ag New indazole derivatives
US20240002390A1 (en) * 2020-12-01 2024-01-04 Hoffmann-La Roche Inc. New indazole acetylene derivatives
WO2022117475A1 (en) * 2020-12-01 2022-06-09 F. Hoffmann-La Roche Ag New indazole derivatives

Also Published As

Publication number Publication date
EP4522113A1 (en) 2025-03-19
US20260007678A1 (en) 2026-01-08
AU2023268579A1 (en) 2024-09-19
CN119173253A (zh) 2024-12-20
CA3255503A1 (en) 2023-11-16
JP2025516543A (ja) 2025-05-30
WO2023217924A1 (en) 2023-11-16
KR20250009977A (ko) 2025-01-20

Similar Documents

Publication Publication Date Title
JP7530391B2 (ja) がんの治療のためのｅｇｆｒ阻害剤
TWI824405B (zh) 四環氧氮呯化合物及其用途
TWI794533B (zh) 稠合環化合物
TWI833773B (zh) 化合物
TW202115073A (zh) 新穎的egfr抑制劑
BR112021008986A2 (pt) composto, composto da fórmula, composto ou sal farmaceuticamente aceitável, composição farmacêutica, métodos para tratar o câncer, para regular a atividade de uma proteína mutante g12c k-ras, para inibir a proliferação de uma população de células, para tratar um distúrbio mediado, para preparar uma proteína e para inibir metástase de tumor e uso
EP4076665B1 (en) Egfr inhibitors
US20260007678A1 (en) Combination of allosteric and orthosteric egfr inhibitors for the treatment of cancer
TW202237611A (zh) 新穎吲唑乙炔衍生物
TW202402276A (zh) 新穎吲唑衍生物
TW202342461A (zh) 雜環化合物及使用方法
HK40115468A (zh) 用於治疗癌症的变构和正构egfr抑制剂的组合产品
TW202204334A (zh) Menin抑制劑及治療癌症之使用方法
RU2853003C1 (ru) Новые индазолацетиленовые производные
HK40071776A (en) Egfr inhibitors
HK40094041A (zh) 新的吲唑乙炔衍生物
HK40063822A (en) Egfr inhibitor for the treatment of cancer